In this Avera Medical Minute, one woman shares her story and the steps she’s taking to lower her risk for breast cancer.

PlaCCine ®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the ...

Brisa Aschebrook-Kilfoy, Associate Professor of Family Medicine at UChicago, is an expert in conducting environmental exposure assessments. She is actively leading efforts to build resources to study ...

Oncologists caution that at-home genetic tests taken up by millions of Americans looking to gauge their cancer risk are not ...

A molar pregnancy, also known as a hydatidiform mole, is an abnormal human pregnancy with no embryo and an overgrowth of the ...

Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, ...

Ask yourself how the genetic test results may affect your life. If the results come back positive, will you take steps to ...

For example, people of eastern European Jewish descent are known to be at a high risk for BRCA1 and BRCA2 gene mutations that increase the risk for breast and ovarian cancers. If you learn that ...

Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...

It induces a specific type of immunity, called Th17 immunity, that seems to prevent suppression of the immune system. The ...

TOP1 is the target of topotecan, which was approved in 1997 by the U.S. Food and Drug Administration (FDA) to treat relapsed ...

Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...